Omega Diagnostics Group PLC Result of General Meeting (9106D)
07 Marzo 2022 - 9:40AM
UK Regulatory
TIDMODX
RNS Number : 9106D
Omega Diagnostics Group PLC
07 March 2022
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulation (EU) No. 596/2014. Upon the publication
of this announcement via the Regulatory Information Service, this
inside information is now considered to be in the public
domain.
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Result of General Meeting
Omega (AIM: ODX), the specialist medical diagnostics company
focused on industry-leading Health & Nutrition and Global
Health (CD4 and COVID-19) products, announces that at the General
Meeting held earlier today, resolution 1 (an ordinary resolution)
passed, but resolution 2 (a special resolution) was not passed.
As a result, the Placing, Subscription and Open Offer will not
take place. The Group is therefore not funded to pursue its growth
strategy as set out in the Circular. The Directors will now need to
reassess the strategy, reflecting on alternative options for
funding for the Company and will update the market in due
course.
A breakdown of the voting results for each resolution is
provided on the Company's website here:
https://www.omegadx.com/Investor-Relations/Corporate-Information
Jag Grewal, Chief Executive Officer, of Omega Diagnostics said:
"The Board is encouraged that resolution 1, increasing the
Directors' authority to allot shares, was approved by shareholders
and notes the views of some retail shareholders with regards to
resolution 2 and their pre-emption rights. Accordingly, the
fundraise will not proceed and the Company will look at other
strategic and funding options."
Capitalised terms not otherwise defined in the text of this
announcement have the meanings given to them in the Company's
circular dated 11 February 2022.
Contacts:
Omega Diagnostics Group PLC www.omegadx.com
Jag Grewal, Chief Executive Officer via Walbrook PR
Chris Lea, Chief Financial Officer
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/Edward Whiley/George Dollemore (Corporate
Finance)
Alice Lane/ Charlotte Sutcliffe
(ECM)
Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Applegarth Mob: 07584 391 303
Sam Allen Mob: 07502 558 258
About Omega Diagnostics Group PLC
Omega manufactures and distributes high quality in-vitro
diagnostic products for use in hospitals, clinics, laboratories and
healthcare practitioners in over 75 countries and specialise in the
areas of health and nutrition and global health.
www.omegadx.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ROMEDLFBLXLXBBD
(END) Dow Jones Newswires
March 07, 2022 10:40 ET (15:40 GMT)
Omega Diagnostics (LSE:ODX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Omega Diagnostics (LSE:ODX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
